Hemoglobinopathies

Home Hemoglobinopathies News & Literature Highlights

EMA Launches Safety Review After Gene Therapy Trial Patient Develops Blood Cancer

This March 2021 news brief announces a safety review by the European Medicines Agency, or EMA, of bluebird bio’s Zynteglo, a gene therapy for thalassemia that is conditionally licensed in Europe.

BioSpace

Class Categories

Hereditary/Acquired Bleeding Disorders

Autoimmune Cytopenias

Bone Marrow Failure Disorders

Hemoglobinopathies

BENIGN HEMATOLOGY BASICS

Benign Hematology Overview

Hereditary and Acquired Bleeding Disorders: Hemophilia

Hereditary and Acquired Bleeding Disorders: von Willebrand Disorders

Autoimmune Cytopenias

Bone Marrow Disorders

Hemoglobinopathies

Bone Marrow Failure Disorders

Meet the Faculty

Resources

Hemoglobinopathies Neurocognitive Risk in Sickle Cell Disease: Utilizing Neuropsychology Services to Manage Cognitive Symptoms and Functional Limitations

Hemoglobinopathies GRNDaD: Big Data and Sickle Cell Disease

Hemoglobinopathies The Impact of VO and VOCs

Hemoglobinopathies An Overview of Sickle Cell Disease (SCD) and the Impact of Hemoglobin S (Hbs) Polymerization, Anemia, and Hemolysis

Hemoglobinopathies About Sickle Cell Disease

Videos

Hemoglobinopathies Understanding Sickle Cell Disease and the Transition Into Adult Care

Hemoglobinopathies Beta-Thalassemia in Adults

Hemoglobinopathies Collaborative Approaches to the Treatment of Beta-Thalassemia